Brokerages predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post earnings per share (EPS) of ($1.65) for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Ultragenyx Pharmaceutical’s earnings. The lowest EPS estimate is ($1.96) and the highest is ($1.46). Ultragenyx Pharmaceutical reported earnings per share of ($1.73) during the same quarter last year, which would suggest a positive year over year growth rate of 4.6%. The company is expected to report its next quarterly earnings report on Tuesday, February 18th.
According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($7.16) per share for the current financial year, with EPS estimates ranging from ($7.46) to ($6.95). For the next year, analysts anticipate that the firm will report earnings of ($5.72) per share, with EPS estimates ranging from ($7.30) to ($2.21). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). The business had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The business’s quarterly revenue was up 119.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.74) earnings per share.
Shares of Ultragenyx Pharmaceutical stock traded up $0.20 on Wednesday, hitting $37.28. 401,800 shares of the company’s stock traded hands, compared to its average volume of 543,912. The stock has a market cap of $2.25 billion, a P/E ratio of -5.04 and a beta of 2.15. The company has a quick ratio of 6.64, a current ratio of 6.79 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $41.64 and its 200 day moving average is $53.91. Ultragenyx Pharmaceutical has a 52-week low of $36.13 and a 52-week high of $74.50.
In related news, CEO Emil D. Kakkis bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average cost of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the purchase, the chief executive officer now owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 2.3% in the second quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock valued at $317,874,000 after buying an additional 112,101 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Ultragenyx Pharmaceutical by 31.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock valued at $292,858,000 after buying an additional 1,110,316 shares during the last quarter. Macquarie Group Ltd. lifted its stake in Ultragenyx Pharmaceutical by 19.6% in the second quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock valued at $50,628,000 after buying an additional 130,561 shares during the last quarter. Northern Trust Corp lifted its stake in Ultragenyx Pharmaceutical by 5.0% in the second quarter. Northern Trust Corp now owns 691,110 shares of the biopharmaceutical company’s stock valued at $43,886,000 after buying an additional 32,812 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Ultragenyx Pharmaceutical by 5.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 318,418 shares of the biopharmaceutical company’s stock valued at $20,220,000 after buying an additional 17,415 shares during the last quarter.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Read More: Institutional Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.